Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OCREVUS vs OCREVUS ZUNOVO
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ocrelizumab is a recombinant humanized monoclonal antibody that selectively targets CD20-positive B cells. It binds to the CD20 antigen expressed on pre-B cells, mature B cells, and memory B cells, but not on plasma cells or hematopoietic stem cells. Binding induces antibody-dependent cellular cytotoxicity and complement-mediated lysis, resulting in B-cell depletion.
OCREVUS ZUNOVO is a recombinant humanized monoclonal antibody that targets CD20-positive B cells. It binds to the CD20 antigen on the surface of pre-B and mature B lymphocytes, leading to antibody-dependent cellular cytotoxicity and complement-mediated lysis, resulting in B-cell depletion.
Relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease,Primary progressive multiple sclerosis (PPMS)
FDA: Treatment of relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.,FDA: Treatment of primary progressive multiple sclerosis (PPMS).
300 mg intravenous infusion followed 2 weeks later by a second 300 mg intravenous infusion; then 600 mg intravenous infusion every 6 months.
Initial dose: 300 mg intravenous infusion over 4 hours followed 2 weeks later by a second 300 mg intravenous infusion over 4 hours. Subsequent doses: 600 mg intravenous infusion over 3.5 hours every 6 months.
Terminal elimination half-life is approximately 26 days (range: 18–39 days) for the 600 mg intravenous dose. This supports every-6-month dosing for sustained B-cell depletion.
Terminal elimination half-life is approximately 26 days (range 20–30 days). This long half-life supports every-6-month dosing. Multiple doses lead to steady-state by 24 weeks.
Ocrelizumab is a monoclonal antibody; it is catabolized into small peptides and amino acids via general protein degradation pathways. No specific metabolic enzymes are involved, and it does not rely on hepatic or renal pathways for clearance.
Ocrevus Zunovo is a monoclonal antibody that is degraded into small peptides and amino acids via general protein catabolism. No specific metabolic pathways or enzymes are involved.
Ocrelizumab is a humanized monoclonal antibody that is catabolized by general protein degradation pathways; it is not excreted renally or hepatically. Less than 1% is eliminated unchanged in urine. Biliary/fecal excretion is negligible as intact Ig G.
Ocrelizumab is metabolized via catabolism into small peptides and amino acids; no specific excretion studies have been conducted. Based on its monoclonal antibody structure, it is not excreted renally or biliary unchanged. Elimination is primarily through intracellular catabolism, with no urinary or fecal excretion of intact drug.
Ocrelizumab is an Ig G1 monoclonal antibody; it does not bind to plasma proteins. Estimated protein binding is negligible (< 1%).
Ocrelizumab is a monoclonal antibody; typical Ig G binding to Fc Rn is p H-dependent, but standard protein binding experiments are not performed. It does not primarily bind to plasma proteins like albumin; thus, reported free fraction is >95% unbound, with minimal nonspecific binding.
Volume of distribution is approximately 2.78 L (range: 1.89–4.23 L), which corresponds to about 0.04 L/kg for a 70 kg adult. This low Vd indicates distribution primarily in the vascular and interstitial spaces.
Volume of distribution is approximately 2.7 L (0.04 L/kg for a 70 kg patient), indicating limited extravascular distribution, consistent with a large monoclonal antibody primarily confined to plasma and interstitial space.
Ocrelizumab is only administered intravenously; bioavailability is 100% by the IV route. Subcutaneous or oral routes are not approved; bioavailability via these routes is unknown.
Subcutaneous: Bioavailability is approximately 50–60% (absolute bioavailability not determined; relative to IV, AUC is 65%). Not available for other routes.
No dose adjustment required for mild to moderate renal impairment; not studied in severe renal impairment (Cr Cl <15 m L/min).
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (GFR <30 m L/min) or end-stage renal disease.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B); not studied in severe hepatic impairment (Child-Pugh C).
No dose adjustment required for mild hepatic impairment (Child-Pugh A). Not studied in moderate or severe hepatic impairment (Child-Pugh B or C).
Safety and efficacy in pediatric patients (<18 years) have not been established; no dosage recommendation.
Safety and efficacy not established in pediatric patients. No approved dosing.
No specific dose adjustment required based on age; consider comorbidities and concomitant medications. Clinical studies included patients up to age 65, limited data in >65 years.
No specific dose adjustment recommended for elderly patients. Clinical studies included patients up to age 65 with no dose modifications.
None
WARNING: INFUSION-RELATED REACTIONS, HYPERSENSITIVITY, AND INCREASED RISK OF INFECTIONS. Infusion-related reactions can occur during or after infusion, including anaphylaxis, acute respiratory distress syndrome, urticaria, and hypotension. Hypersensitivity reactions, including anaphylaxis, have been reported. Ocrevus Zunovo increases the risk of upper respiratory tract infections, lower respiratory tract infections, and herpes infections. Patients should be monitored during infusion and for at least one hour post-infusion.
Infusion reactions: May require premedication; monitor during infusion,Infections: Increased risk, including herpes zoster and respiratory tract infections; screen for hepatitis B virus before initiation,Progressive multifocal leukoencephalopathy (PML): Rare but serious; discontinue if suspected,Immunoglobulin levels: Monitor; low Ig G associated with increased infection risk,Malignancies: Possible increased risk, particularly breast cancer,Fetal harm: Avoid in pregnancy; women of childbearing potential should use contraception
Infusion reactions: premedicate with corticosteroids and antihistamines; monitor during infusion and for at least 1 hour after.,Infections: increased risk, especially upper and lower respiratory tract infections and herpes infections; delay administration in patients with active infection.,Hepatitis B virus reactivation: screen all patients for HBV; do not start in patients with active hepatitis.,Progressive multifocal leukoencephalopathy (PML): withhold if PML suspected; discontinue if confirmed.,Vaccination: administer all required vaccines at least 4 weeks prior to starting therapy; live vaccines not recommended during treatment.,Immunoglobulin levels: monitor; consider discontinuation if low.,Fetal harm: may cause fetal harm; advise effective contraception during and for 3 months after last infusion.
Active hepatitis B virus infection,History of life-threatening infusion reaction to ocrelizumab,Severe, active infections (e.g., tuberculosis, sepsis)
Active hepatitis B virus infection.,History of life-threatening infusion reaction to Ocrevus Zunovo.,Known active infections (e.g., tuberculosis, sepsis).,Severe immunocompromised state (e.g., current immunosuppressive therapy).
No food interactions have been reported with ocrelizumab. The medication is administered intravenously, and there are no dietary restrictions required.
No known food interactions. Ocrevus Zunovo may be administered without regard to meals.
Ocrevus (ocrelizumab) is a humanized monoclonal antibody that depletes CD20-positive B cells. Ig G antibodies cross the placenta, especially in the third trimester. There are no adequate and well-controlled studies in pregnant women. In animal studies, ocrelizumab was not teratogenic but caused B-cell depletion in offspring. Use is not recommended unless the benefit outweighs the risk. Based on limited human data, there is no known structural teratogenicity; however, the potential for B-cell depletion and immunosuppression in the fetus, particularly if administered during the second and third trimesters, exists.
Ocrelizumab (OCREVUS ZUNOVO) is a humanized anti-CD20 monoclonal antibody that crosses the placenta. In first trimester, B-cell depletion may occur; second and third trimester exposure is associated with fetal B-cell lymphocytopenia and potential increased infection risk. Animal studies show no direct teratogenicity, but human data are limited. Avoid during pregnancy unless benefit outweighs risk.
It is not known whether ocrelizumab is excreted in human milk. Human Ig G is present in breast milk, and limited data suggest that monoclonal antibodies are transferred in small amounts. The M/P ratio is not established for ocrelizumab. Caution should be exercised; the decision to breastfeed should consider the mother's need for therapy, the potential for drug excretion, and the infant's immune status.
Ocrelizumab is excreted into human breast milk in low amounts (estimated M/P ratio not established; Ig G monoclonal antibodies have limited transfer). Preterm infants and neonates may have reduced absorption. Consider developmental benefits of breastfeeding, maternal need for therapy, and potential infant immunosuppression. Monitor infant for B-cell levels and infections.
No specific dose adjustments are recommended for pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased plasma volume) may affect drug levels, but no dose adjustment guidelines are established. The manufacturer advises avoiding use in pregnancy unless clearly necessary, and no dose modification is specified.
No formal dosing adjustments for pregnancy. Pharmacokinetics may change due to increased plasma volume and altered clearance, but no well-controlled studies. Generally, maintain same dose; if severe infusion reaction risk, consider slower infusion rate or premedication. Postpartum, consider timing of next dose relative to breastfeedin if applicable.
Ocrevus (ocrelizumab) is a recombinant humanized monoclonal antibody that selectively targets CD20-positive B cells. It is administered as an intravenous infusion. Premedication with methylprednisolone, an antihistamine, and an antipyretic is required to reduce infusion-related reactions. Screen for hepatitis B virus (HBV) infection before initiating therapy; do not use in patients with active HBV. Monitor for infections, especially upper respiratory tract infections, herpes, and urinary tract infections. Live and live-attenuated vaccines are contraindicated during treatment and until B-cell repletion. Administer all required vaccines at least 4-6 weeks before starting therapy. No dose adjustment needed for renal or hepatic impairment.
Ocrevus Zunovo (ocrelizumab/hyaluronidase) is a subcutaneous formulation of ocrelizumab with recombinant human hyaluronidase to facilitate absorption. Administer subcutaneously in the abdomen over approximately 10 minutes. Premedicate with methylprednisolone (100 mg IV or equivalent oral) and an antihistamine (e.g., diphenhydramine 50 mg) approximately 30 minutes prior to each injection to reduce infusion reactions. Monitor for injection-site reactions, including erythema, pain, and swelling. Live-attenuated vaccines are contraindicated during treatment and until B-cell repletion. Do not administer if active infection is present.
Ocrevus is given as an intravenous infusion every 6 months.,You will receive premedication before each infusion to reduce the risk of infusion reactions.,Report any symptoms of infection promptly, including fever, cough, or painful urination.,Avoid receiving live vaccines while on Ocrevus and for a period after treatment.,Tell your doctor if you have a history of hepatitis B infection.,You may be at increased risk for certain cancers, including breast cancer; follow recommended screening.,Inform all healthcare providers that you are taking Ocrevus.
Ocrevus Zunovo is given as a subcutaneous injection every 6 months after the initial two doses separated by 2 weeks.,You will receive premedication before each injection to reduce the risk of allergic reactions.,Common side effects include injection-site reactions, headache, and upper respiratory tract infections.,Avoid live vaccines (e.g., MMR, varicella, intranasal flu) during treatment and for at least 4 weeks before starting.,Contact your healthcare provider immediately if you develop symptoms of infection, such as fever, chills, or cough.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OCREVUS vs OCREVUS ZUNOVO, answered by our medical review team.
OCREVUS is a CD20-directed monoclonal antibody that works by Ocrelizumab is a recombinant humanized monoclonal antibody that selectively targets CD20-positive B cells. It binds to the CD20 antigen expressed on pre-B cells, mature B cells, and memory B cells, but not on plasma cells or hematopoietic stem cells. Binding induces antibody-dependent cellular cytotoxicity and complement-mediated lysis, resulting in B-cell depletion.. OCREVUS ZUNOVO is a CD20-directed monoclonal antibody that works by OCREVUS ZUNOVO is a recombinant humanized monoclonal antibody that targets CD20-positive B cells. It binds to the CD20 antigen on the surface of pre-B and mature B lymphocytes, leading to antibody-dependent cellular cytotoxicity and complement-mediated lysis, resulting in B-cell depletion.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OCREVUS and OCREVUS ZUNOVO depend on the specific clinical indication. These are both CD20-directed monoclonal antibody agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OCREVUS is: 300 mg intravenous infusion followed 2 weeks later by a second 300 mg intravenous infusion; then 600 mg intravenous infusion every 6 months.. The standard adult dose of OCREVUS ZUNOVO is: Initial dose: 300 mg intravenous infusion over 4 hours followed 2 weeks later by a second 300 mg intravenous infusion over 4 hours. Subsequent doses: 600 mg intravenous infusion over 3.5 hours every 6 months.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OCREVUS and OCREVUS ZUNOVO in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OCREVUS is classified as Category C. Ocrevus (ocrelizumab) is a humanized monoclonal antibody that depletes CD20-positive B cells. IgG antibodies cross the placenta, especially in the third trimester. There are no ade. OCREVUS ZUNOVO is classified as Category C. Ocrelizumab (OCREVUS ZUNOVO) is a humanized anti-CD20 monoclonal antibody that crosses the placenta. In first trimester, B-cell depletion may occur; second and third trimester expo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.